AN2 Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2017-01-01
- Employees
- 41
- Market Cap
- $34.9M
- Introduction
AN2 Therapeutics, Inc. operates as a global health biopharmaceutical company. The firm focuses on modern biomedical and drug development to provide transformational medicines for patients suffering from infectious diseases. The company was founded by Eric Easom, George Harrison Talbot, Joseph S. Zakrzewski and Michael R.K. Alley and is headquartered in Menlo...
An Observational Study to Evaluate Clinical Characteristics of Adult Patients With Suspected or Confirmed Melioidosis
- Conditions
- First Posted Date
- 2023-10-18
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- AN2 Therapeutics, Inc
- Target Recruit Count
- 200
- Registration Number
- NCT06089668
- Locations
- 🇱🇦
Mahosot Hospital, Vientiane, Lao People's Democratic Republic
🇹🇭Srinagarind Hospital, Khon Kaen, Thailand
🇹🇭Sunpasitthiprasong Hospital, Ubon Ratchathani, Thailand
A Study to Assess the Effects of Epetraborole on the QT Interval in Healthy Adult Subjects
- Conditions
- Interventions
- First Posted Date
- 2023-08-16
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- AN2 Therapeutics, Inc
- Target Recruit Count
- 24
- Registration Number
- NCT05995444
- Locations
- 🇺🇸
423001, Tempe, Arizona, United States
Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease
- Conditions
- Interventions
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- AN2 Therapeutics, Inc
- Target Recruit Count
- 314
- Registration Number
- NCT05327803
- Locations
- 🇺🇸
423060, Baltimore, Maryland, United States
🇺🇸423074, Boston, Massachusetts, United States
🇺🇸423079, Cleveland, Ohio, United States
A Study of Epetraborole Tablets in Subjects With Degrees of Renal Function
- First Posted Date
- 2022-03-17
- Last Posted Date
- 2022-07-15
- Lead Sponsor
- AN2 Therapeutics, Inc
- Target Recruit Count
- 40
- Registration Number
- NCT05283746
- Locations
- 🇺🇸
Nucleus Network, Saint Paul, Minnesota, United States
🇺🇸Advanced Pharma CR, Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
Phase 1 Study of Epetraborole Tablets
- First Posted Date
- 2021-05-19
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- AN2 Therapeutics, Inc
- Target Recruit Count
- 51
- Registration Number
- NCT04892641
- Locations
- 🇦🇺
CMAX Clinical Research, Adelaide, South Australia, Australia